Increased PFAS Exposure Linked to High Blood Pressure in Aging Women


According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.

This article was originally published on

Woman checking her blood pressure.

Increased exposure to per- and polyfluoroalkyl substances (PFAS), or “forever chemicals”, have been linked to an increased risk of incident hypertension in women.

An analysis of data from the Study of Women’s Health Across the Nation-Multi-Pollutant Study (SWAN-MPS), results of the study indicate women in the highest one-third of concentrations of perfluorooctane sulfonic acid (n-PFOS), perfluorooctanoic acid (PFOA), and 2-(N-ethyl-perfluorooctane sulfonamido) acetic acid (EtFOSAA) had 42%, 47%, and 42% higher risks, respectively, of developing hypertension, compared to women in the lowest one-third concentrations of these PFAS.

“Women seem to be particularly vulnerable when exposed to these chemicals,” said lead investigator Ning Ding, PhD, MPH, a post-doctoral fellow in the department of epidemiology at the University of Michigan School of Public Health in Ann Arbor, Michigan, in a statement from the American Heart Association. “Our study is the first to examine the association between ‘forever chemicals’ and hypertension in middle-aged women. Exposure may be an underappreciated risk factor for women’s cardiovascular disease risk.”

An extension of the multisite, multiracial, and multiethnic, community-based longitudinal SWAN study, SWAN-MPS was initiated in 2006 with the intent of examining the effects of multiple pollutants on long-term health in midlife women. Of the more than 1600 women included in SWAN-MPS, 1058 midlife women without a history of hypertension with annual follow-up visits from 1999-2017 were identified for inclusion in the current study. For the purpose of analysis, Cox proportional hazards models were used to calculate hazard ratios and quartile g-computation was used to assess the joint effect of PFAS mixtures.

A total of 7 different PFAS were identified for inclusuio9n in the investigators’ analyses. These included perfluorohexane sulfonate (PFHxS), linear perfluorooctane sulfonate (n-PFOS), sum of branched isomers of PFOS (Sm-PFOS), linearperfluorooctanoate(n-PFOA),sumofbranchedPFOA, perfluorononanoate, perfluorodecanoate,perfluoroundecanoate, perfluorododecanoate, EtFOSAA,and2-(N-methyl-perfluorooctane sulfonamido)acetate(MeFOSAA). Concentrations of each were determined through use of online solid-phase extraction-high performance liquid chromatography-isotope dilution-tandem mass spectrometry.

From this cohort, investigators obtained data related to 11,722 person-years of follow-up. During this period, 470 women developed incident hypertension, which correlates to 40.1 cases per 1000 person-years. When compared to those in the lowest tertile of serum concentrations, an increased risk of hypertension was observed for women in the highest tertile of PFOS (HR, 1.42 [95% CI, 1.19–1.68]; P=.01), for PFOA (HR, 1.47 [95% CI, 1.24–1.75]; P=.01), and for EtFOSAA (HR, 1.42 [95% CI, 1.19–1.70]; P=.01).

Investigators pointed out there were no significant associations observed for perfluorononanoate and perfluorohexane sulfonate. Further analysis suggested those in the highest tertile of overall PFAS concentrations had an increased risk of incident hypertension (HR, 1.71 [95% CI, 1.15–2.54]; P=.008) compared to those in the lowest tertile of overall PFAS concentrations.

“It’s important to note that we examined individual PFAS as well as several PFAS together, and we found that the combined exposure to multiple PFAS had a stronger effect on blood pressure,” said senior investigator Sung Kyun Park, ScD, MPH, an associate professor of epidemiology and environmental health sciences at the University of Michigan School of Public Health, in the aforementioned statement. “Some states are beginning to ban the use of PFAS in food packaging and cosmetic and personal care products. Our findings make it clear that strategies to limit the widespread use of PFAS in products need to be developed. Switching to alternative options may help reduce the incidence of high blood pressure risk in midlife women.”

This study, “Per- and Polyfluoroalkyl Substances and Incident Hypertension in Multi-Racial/Ethnic Women: The Study of Women's Health Across the Nation,” was published in Hypertension.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit:
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
© 2024 MJH Life Sciences

All rights reserved.